UY28408A1 - Agentes terapeuticos - Google Patents
Agentes terapeuticosInfo
- Publication number
- UY28408A1 UY28408A1 UY28408A UY28408A UY28408A1 UY 28408 A1 UY28408 A1 UY 28408A1 UY 28408 A UY28408 A UY 28408A UY 28408 A UY28408 A UY 28408A UY 28408 A1 UY28408 A1 UY 28408A1
- Authority
- UY
- Uruguay
- Prior art keywords
- linked
- methods
- compounds
- therapeutic agents
- nr1h2
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000004311 liver X receptors Human genes 0.000 abstract 2
- 108090000865 liver X receptors Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 abstract 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0316232.8A GB0316232D0 (en) | 2003-07-11 | 2003-07-11 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY28408A1 true UY28408A1 (es) | 2005-02-28 |
Family
ID=27741983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY28408A UY28408A1 (es) | 2003-07-11 | 2004-07-09 | Agentes terapeuticos |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7432288B2 (https=) |
| EP (1) | EP1646626B1 (https=) |
| JP (1) | JP2007521312A (https=) |
| KR (1) | KR20060035748A (https=) |
| CN (1) | CN1823061A (https=) |
| AR (1) | AR045721A1 (https=) |
| AT (1) | ATE399777T1 (https=) |
| AU (1) | AU2004255999B2 (https=) |
| BR (1) | BRPI0412472A (https=) |
| CA (1) | CA2532056A1 (https=) |
| DE (1) | DE602004014773D1 (https=) |
| ES (1) | ES2308204T3 (https=) |
| GB (1) | GB0316232D0 (https=) |
| IL (1) | IL172760A0 (https=) |
| IS (1) | IS8293A (https=) |
| MX (1) | MXPA06000414A (https=) |
| MY (1) | MY135821A (https=) |
| NO (1) | NO20060081L (https=) |
| RU (1) | RU2006102130A (https=) |
| SA (1) | SA04250204B1 (https=) |
| TW (1) | TW200503691A (https=) |
| UA (1) | UA82109C2 (https=) |
| UY (1) | UY28408A1 (https=) |
| WO (1) | WO2005005417A1 (https=) |
| ZA (1) | ZA200600222B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1634877B1 (en) * | 2004-08-17 | 2011-06-22 | Simpson Biotech Co., Ltd. | Mixture and compounds from mycelia of antrodia camphorata and use thereof |
| US7505238B2 (en) * | 2005-01-07 | 2009-03-17 | Agnes Neves Woo | ESD configuration for low parasitic capacitance I/O |
| SE0500055D0 (sv) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
| CA2592771A1 (en) | 2005-01-10 | 2006-07-13 | Astrazeneca Ab | Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators |
| WO2007128458A1 (en) * | 2006-04-28 | 2007-11-15 | Laboratorios Del Dr. Esteve, S.A. | Bicyclic tetrahydropyrrole compounds |
| ES2528797T3 (es) | 2006-08-21 | 2015-02-12 | Genentech, Inc. | Compuestos de aza-benzotiofenilo y métodos de uso |
| CN101456863B (zh) * | 2007-12-14 | 2012-04-25 | 华北制药集团新药研究开发有限责任公司 | Lxr激动剂及其制备方法和用途 |
| MX2010014565A (es) | 2008-07-01 | 2011-03-04 | Genentech Inc | Isoindolona y metodos de uso. |
| RU2509078C2 (ru) | 2008-07-01 | 2014-03-10 | Дженентек, Инк. | Бициклические гетероциклы в качестве ингибиторов киназы мек |
| US20130274212A1 (en) | 2010-09-07 | 2013-10-17 | Snu R&Db Foundation | Sesterterpene Compounds and Use Thereof |
| JP2013544837A (ja) | 2010-12-03 | 2013-12-19 | アラーガン インコーポレイテッド | スフィンゴシン−１−リン酸（ｓ１ｐ）受容体モジュレーターとしての新規オキシムアゼチジン誘導体 |
| AU2011336970A1 (en) | 2010-12-03 | 2013-07-11 | Allergan, Inc. | Novel oxime derivatives as sphingosine 1-phosphate (S1P) receptor modulators |
| US10669296B2 (en) | 2014-01-10 | 2020-06-02 | Rgenix, Inc. | LXR agonists and uses thereof |
| CA3010883A1 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
| EP3713575A4 (en) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | POLYMORPHS AND THEIR USES |
| HUE067466T2 (hu) | 2019-12-13 | 2024-10-28 | Inspirna Inc | Fémsók és alkalmazásuk |
| US11753374B2 (en) * | 2020-11-18 | 2023-09-12 | Southern Reserach Institute | Compounds for the treatment of acute and chronic kidney disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2338866A1 (en) | 1998-07-30 | 2000-02-10 | Japan Tobacco Inc. | Disubstituted maleimide compound and pharmaceutical use thereof |
| ATE284387T1 (de) * | 1998-10-08 | 2004-12-15 | Smithkline Beecham Plc | 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) |
| JP2004500332A (ja) * | 1999-07-08 | 2004-01-08 | テュラリク インコーポレイテッド | Ｈｄｌコレステロール値を上昇させる組成物および方法 |
| AU6593600A (en) | 1999-08-20 | 2001-03-19 | Rei Asakai | Drugs inhibiting cell death |
| GB0008264D0 (en) | 2000-04-04 | 2000-05-24 | Smithkline Beecham Plc | Novel method and compounds |
-
2003
- 2003-07-11 GB GBGB0316232.8A patent/GB0316232D0/en not_active Ceased
-
2004
- 2004-06-29 TW TW093119064A patent/TW200503691A/zh unknown
- 2004-07-05 SA SA4250204A patent/SA04250204B1/ar unknown
- 2004-07-08 KR KR1020067000712A patent/KR20060035748A/ko not_active Withdrawn
- 2004-07-08 EP EP04749150A patent/EP1646626B1/en not_active Expired - Lifetime
- 2004-07-08 WO PCT/SE2004/001114 patent/WO2005005417A1/en not_active Ceased
- 2004-07-08 BR BRPI0412472-3A patent/BRPI0412472A/pt not_active IP Right Cessation
- 2004-07-08 ES ES04749150T patent/ES2308204T3/es not_active Expired - Lifetime
- 2004-07-08 CA CA002532056A patent/CA2532056A1/en not_active Abandoned
- 2004-07-08 MX MXPA06000414A patent/MXPA06000414A/es not_active Application Discontinuation
- 2004-07-08 AT AT04749150T patent/ATE399777T1/de not_active IP Right Cessation
- 2004-07-08 AU AU2004255999A patent/AU2004255999B2/en not_active Ceased
- 2004-07-08 CN CNA2004800198411A patent/CN1823061A/zh active Pending
- 2004-07-08 DE DE602004014773T patent/DE602004014773D1/de not_active Expired - Fee Related
- 2004-07-08 AR ARP040102419A patent/AR045721A1/es not_active Application Discontinuation
- 2004-07-08 JP JP2006520138A patent/JP2007521312A/ja not_active Withdrawn
- 2004-07-08 RU RU2006102130/04A patent/RU2006102130A/ru not_active Application Discontinuation
- 2004-07-08 US US10/564,235 patent/US7432288B2/en not_active Expired - Fee Related
- 2004-07-09 UY UY28408A patent/UY28408A1/es unknown
- 2004-07-09 MY MYPI20042745A patent/MY135821A/en unknown
- 2004-08-07 UA UAA200600272A patent/UA82109C2/uk unknown
-
2005
- 2005-12-22 IL IL172760A patent/IL172760A0/en unknown
-
2006
- 2006-01-05 NO NO20060081A patent/NO20060081L/no not_active Application Discontinuation
- 2006-01-10 ZA ZA200600222A patent/ZA200600222B/en unknown
- 2006-02-09 IS IS8293A patent/IS8293A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2532056A1 (en) | 2005-01-20 |
| NO20060081L (no) | 2006-02-08 |
| IS8293A (is) | 2006-02-09 |
| BRPI0412472A (pt) | 2006-09-19 |
| US20060235015A1 (en) | 2006-10-19 |
| TW200503691A (en) | 2005-02-01 |
| AU2004255999A1 (en) | 2005-01-20 |
| AU2004255999B2 (en) | 2007-08-02 |
| JP2007521312A (ja) | 2007-08-02 |
| ATE399777T1 (de) | 2008-07-15 |
| KR20060035748A (ko) | 2006-04-26 |
| US7432288B2 (en) | 2008-10-07 |
| MY135821A (en) | 2008-07-31 |
| UA82109C2 (uk) | 2008-03-11 |
| WO2005005417A1 (en) | 2005-01-20 |
| IL172760A0 (en) | 2006-04-10 |
| AR045721A1 (es) | 2005-11-09 |
| CN1823061A (zh) | 2006-08-23 |
| GB0316232D0 (en) | 2003-08-13 |
| ES2308204T3 (es) | 2008-12-01 |
| SA04250204B1 (ar) | 2008-03-23 |
| ZA200600222B (en) | 2007-04-25 |
| HK1088320A1 (en) | 2006-11-03 |
| EP1646626B1 (en) | 2008-07-02 |
| RU2006102130A (ru) | 2007-08-20 |
| EP1646626A1 (en) | 2006-04-19 |
| DE602004014773D1 (de) | 2008-08-14 |
| MXPA06000414A (es) | 2006-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY28407A1 (es) | Agentes terapeuticos | |
| UY28408A1 (es) | Agentes terapeuticos | |
| CL2007003440A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida | |
| ECSP088405A (es) | Nuevos derivados de pirimidina y su uso en terapia, así como el uso de derivados de pirimidina en la fabricación de un medicamento para la prevención y/o tratamiento de la enfermedad de alzheimer | |
| UY28369A1 (es) | Agentes terapéuticos | |
| BRPI0606391A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, formulação farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| UY28752A1 (es) | Agentes terapeuticos | |
| PA8564001A1 (es) | Aza-arilpiperazinas | |
| PA8604201A1 (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades | |
| PA8622001A1 (es) | Derivados de sulfonamida para el tratamiento de enfermedades | |
| NO20073248L (no) | Derivater av isotiazol-3(2H)-on 1,1-dioksider som lever X reseptor modulatorer | |
| PA8603001A1 (es) | Compuestos utiles para el tratamiento de enfermedades | |
| UY28377A1 (es) | Agentes terapeuticos | |
| PA8627001A1 (es) | Compuestos para el tratamiento de enfermedades | |
| PA8542601A1 (es) | Bifenilcarboxamidas reductoras de lipidos | |
| SE0500056D0 (sv) | Therapeutic agents 4 | |
| BR0318242A (pt) | derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação | |
| CL2004000779A1 (es) | Compuestos derivados de 3-azabiciclo [3.2.1]octano, composicion farmaceutica, procedimiento de preparacion, util para preparar medicamentos para tratar sindrome de intestino irritable, estrenimiento, nauseas, vomitos, disfuncion sexual, alzheimer, en | |
| SE0500058D0 (sv) | Therapeutic agents 5 | |
| BR0316193A (pt) | Composto, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica | |
| AR037792A1 (es) | Compuestos derivados de benzotiazol, su uso, un procedimiento para su obtencion y medicamentos que los contienen | |
| SE0500054D0 (sv) | Therapeutic agents 2 | |
| UY29635A1 (es) | Derivados anilinicos de 1,1-dioxidos de isotiazol-3(2h)-ona como moduladores del receptor hepatico x | |
| BR0315951A (pt) | Compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica | |
| UY29634A1 (es) | Derivados no anilinicos de 1,1-dioxidos de isotiazol-3(2h)-ona como moduladores de los receptores hepaticos x |